Braxia Scientific Corp.
BRAX
CNSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.50% | 26.94% | 36.59% | 32.34% | 39.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.50% | 26.94% | 36.59% | 32.34% | 39.72% |
| Cost of Revenue | -14.53% | 6.22% | 57.00% | 47.29% | 46.78% |
| Gross Profit | 737.50% | 327.56% | -22.26% | -55.79% | -58.62% |
| SG&A Expenses | -59.42% | -84.61% | -30.12% | 9.86% | -21.72% |
| Depreciation & Amortization | -61.19% | -60.87% | 69.23% | 2,249.02% | 3,008.89% |
| Other Operating Expenses | -- | -- | -20.51% | -- | -- |
| Total Operating Expenses | -53.14% | -64.57% | -6.62% | 16.38% | -5.88% |
| Operating Income | 64.14% | 89.24% | 26.81% | -13.21% | 11.79% |
| Income Before Tax | 58.31% | 88.68% | 21.32% | -6.59% | 20.09% |
| Income Tax Expenses | -- | -- | -- | -202.24% | -- |
| Earnings from Continuing Operations | 58.31% | 88.68% | 21.32% | -5.29% | 20.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.31% | 88.68% | 21.32% | -5.29% | 20.09% |
| EBIT | 64.14% | 89.24% | 26.81% | -13.21% | 11.79% |
| EBITDA | 63.20% | 90.99% | 29.22% | -5.73% | 18.63% |
| EPS Basic | 62.12% | 90.00% | 39.47% | 17.39% | 44.54% |
| Normalized Basic EPS | 60.98% | 88.64% | 39.13% | 8.70% | 44.59% |
| EPS Diluted | 62.12% | 90.00% | 39.47% | 17.39% | 44.54% |
| Normalized Diluted EPS | 60.98% | 88.64% | 39.13% | 8.70% | 44.59% |
| Average Basic Shares Outstanding | 9.55% | 16.89% | 32.80% | 27.53% | 42.80% |
| Average Diluted Shares Outstanding | 9.55% | 16.89% | 32.80% | 27.53% | 42.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
